Clinical Guides
Chronic Kidney Disease
A clinically focused guide to confirming, classifying and slowing chronic kidney disease, integrating albuminuria, cause, cardiovascular risk, safe prescribing, complications, nephrology referral and feasible kidney-replacement or conservative care in India.
MedNext Academy | 16 min read
Chronic Kidney Disease
A clinically focused guide to confirming, classifying and slowing chronic kidney disease, integrating albuminuria, cause, cardiovascular risk, safe prescribing, complications, nephrology referral and feasible kidney-replacement or conservative care in India.
Summary
Chronic kidney disease (CKD) means abnormalities of kidney structure or function present for at least three months with implications for health. It is classified by cause, glomerular filtration category and albuminuria category, often summarized as CGA. A single reduced estimated glomerular filtration rate (eGFR), one positive dipstick or one elevated urine albumin-to-creatinine ratio (ACR) does not establish chronicity. First exclude acute kidney injury, repeat abnormal measurements at an appropriate interval and retrieve older results. Persistent eGFR below 60 mL/min/1.73 m² qualifies even without another marker; G1 or G2 requires a marker of kidney damage such as albuminuria, urine-sediment abnormality, structural disease, histology or a transplant.
Care has four linked aims: identify a treatable cause, reduce progression, reduce cardiovascular and acute-kidney-injury risk, and detect complications early. Blood-pressure control, diabetes care, renin-angiotensin-system blockade for appropriate albuminuric disease, sodium-glucose cotransporter-2 inhibition for eligible patients, smoking cessation, physical activity, nutrition and lipid management are individualized rather than bundled blindly. Every encounter should review nephrotoxins, over-the-counter medicines and dose appropriateness.
Monitor haemoglobin, potassium, bicarbonate, calcium, phosphate and other parameters according to stage and trajectory. Anaemia, mineral-bone disorder, acidosis, hyperkalaemia, fluid overload and malnutrition require cause-specific assessment; treating a laboratory value without context can cause harm. Referral is guided by cause, progression, albuminuria, haematuria, resistant hypertension, complications and predicted kidney-failure risk, not eGFR alone. Preparation for transplant, dialysis access or peritoneal dialysis should begin before an emergency, alongside an honest option of comprehensive conservative care. Indian pathways vary substantially in laboratory, nephrology, transplant and dialysis access. This draft has been reviewed by the MedNext Clinical Team and is not a patient-specific treatment plan.
How Common Is It?
CKD is a major global noncommunicable disease and an important amplifier of cardiovascular disease, infection, medicine toxicity and hospital admission. Its apparent prevalence depends on age, diabetes and hypertension burden, the eGFR equation, whether ACR is measured, and whether abnormalities are confirmed after three months. Cross-sectional surveys that use one creatinine or one urine result may overestimate persistent disease, while programmes that omit urine albumin miss people with preserved eGFR but important glomerular damage.
India has large differences in population risk, primary-care testing, creatinine calibration, albuminuria access and referral. Tertiary nephrology cohorts over-represent advanced glomerular disease and late presentation; community screening finds a different spectrum. This guide therefore does not claim one definitive contemporary Indian prevalence. At service level, the more useful measures are how many high-risk people receive both eGFR and urine ACR, how often abnormal tests are confirmed, whether cause and progression are documented, and how many reach specialist care before a dialysis emergency.
Diabetes and hypertension account for much CKD burden, but they should not become automatic labels. Glomerular disease, hereditary disorders, obstructive uropathy, recurrent stones or infection, tubulointerstitial disease, congenital abnormalities and prior acute kidney injury remain important. Cardiovascular events are more common than kidney failure in many lower-risk patients, so a kidney-only conversation is incomplete. Albuminuria adds prognostic information at every eGFR.
Measured burden also reflects inequity. Rural distance, cost of ACR, intermittent medication supply and delayed ultrasound or biopsy can prevent etiological diagnosis. Women, older adults and people with low muscle mass may have deceptively low creatinine despite reduced filtration. Conversely, muscular people can have higher creatinine without intrinsic disease. Reliable surveillance should report age, sex, eGFR and ACR categories, confirmation, diabetes status and assay method rather than converting a single abnormal screen into a permanent diagnosis.
Risk Factors
People at increased risk include those with diabetes, hypertension, cardiovascular disease, previous acute kidney injury, heart failure, obesity, recurrent urinary infection, stones, obstruction, systemic autoimmune disease, chronic infection, HIV, malignancy, a solitary kidney, congenital urinary abnormalities or a family history of kidney failure. Low birth weight and childhood kidney disease may reduce nephron reserve. Older age increases CKD frequency but does not make every decline benign. Pregnancy can reveal previously unrecognized disease, and CKD increases maternal and fetal risk.
Medicine and toxin exposure matters. Regular NSAID use, some traditional or unlabelled remedies, prior nephrotoxic antimicrobials, lithium, calcineurin inhibitors, chemotherapy and recurrent contrast-associated illness may contribute in the appropriate context. The history should record dose, duration and indication rather than declaring causation from exposure alone. Occupational heat stress, dehydration, heavy metals or agrochemicals may warrant targeted evaluation, but geographic labels should not substitute for evidence. Recurrent untreated obstruction from stones or prostate disease can be preventable.
Progression risk is not identical to presence risk. Persistent higher albuminuria, lower eGFR, rapid confirmed decline, uncontrolled blood pressure, ongoing diabetes-related injury, smoking, repeated AKI and active inflammatory disease predict concern. KDIGO recommends using validated kidney-failure risk equations in CKD G3 to G5 where applicable, while recognizing that validation, competing mortality and treatment patterns affect interpretation. A calculated percentage supports, rather than replaces, clinical judgment.
Social and system risks can accelerate disease: fragmented prescriptions, unaffordable monitoring, lack of a named clinician for potassium results, travel distance, low health literacy and emergency-only dialysis access. Diet advice copied from another country may be unaffordable or culturally unusable. Risk assessment should identify what can change, what needs specialist investigation and what threatens safe follow-up. Protective care includes vaccination as locally indicated, infection prevention, avoidance of volume depletion and a clear plan for intercurrent illness, but generic sick-day instructions must specify which medicines, circumstances and restart checks apply.
Diagnosis
CKD diagnosis requires proof of chronicity, classification and a cause-oriented assessment. Record both eGFR and ACR because either alone incompletely describes prognosis. Do not apply an eGFR equation during rapidly changing creatinine as if it represented stable filtration.
History
Retrieve every available creatinine, ACR, urinalysis and imaging result. Ask about diabetes and blood-pressure duration, oedema, nocturia, visible haematuria, frothy urine, stones, recurrent infection, retention, rash, arthritis, hearing or visual disorders, neuropathy and systemic symptoms. Document birth and childhood urinary history, pregnancies, family pedigree, consanguinity, kidney failure or cystic disease. Reconcile prescribed, non-prescription, injected, herbal and traditional products. Ask about prior AKI, dialysis, contrast, occupational exposure and barriers to testing or treatment.
Examination
Measure blood pressure using a validated device and standardized technique where feasible, including posture when indicated. Assess weight trend, volume status, oedema, venous pressure, lungs and cardiac disease. Examine skin, joints, eyes, peripheral pulses and signs of systemic or hereditary disease. Look for bladder distension, enlarged kidneys or abdominal bruits when clinically relevant. A normal examination does not exclude significant CKD, while oedema may reflect heart, liver or venous disease rather than kidney failure alone.
Investigations
Repeat creatinine and calculate eGFR; quantify urine ACR on a preferably early-morning sample and confirm persistent moderate albuminuria when clinically stable. Examine urinalysis and sediment, CBC, electrolytes and bicarbonate. Add calcium, phosphate, alkaline phosphatase, parathyroid hormone, iron indices, HbA1c or glucose and lipids according to stage and clinical question. Ultrasound assesses size, symmetry, obstruction, cysts and anatomy. Serology, electrophoresis, genetic testing or biopsy is targeted to phenotype and specialist input. Stage eGFR as G1 at least 90, G2 60 to 89, G3a 45 to 59, G3b 30 to 44, G4 15 to 29 and G5 below 15. Stage ACR as A1 below 30 mg/g, A2 30 to 300 and A3 above 300, using laboratory units carefully.
Differential Diagnosis
The first alternative is acute kidney injury or acute-on-chronic kidney disease. A recent creatinine rise, oliguria, sepsis, volume loss, obstruction or nephrotoxic exposure requires acute assessment rather than waiting three months. Older stable results prove chronicity more reliably than assumptions based on anaemia or ultrasound. Small echogenic kidneys support chronic disease but are not universal; diabetic, infiltrative, cystic and some early diseases may retain normal or enlarged kidneys. A normal-sized kidney does not exclude chronic damage.
Creatinine-based eGFR can misclassify people with unusually low or high muscle mass, amputation, paralysis, severe malnutrition, bodybuilding, creatine use or rapidly changing physiology. Cystatin C may refine assessment when available and when the result will change a decision, but inflammation, thyroid disease and corticosteroids can affect it. A modest isolated creatinine elevation caused by tubular secretion inhibition does not necessarily represent matching structural decline. Laboratory error and specimen issues also warrant confirmation.
Albuminuria should be separated from transient findings after fever, vigorous exercise, urinary infection, menstruation, heart failure or marked hyperglycaemia. Dipstick protein is not a substitute for quantified ACR and may miss non-albumin proteins. Haematuria may arise from infection, stones, malignancy, menstruation or glomerular disease. Albuminuria plus dysmorphic red cells or casts changes concern, but microscopy quality matters.
For cause, distinguish diabetes-related disease from primary glomerulopathy, hypertensive vascular disease, interstitial nephritis, reflux or obstructive nephropathy, hereditary cystic disease, monoclonal gammopathy and systemic immune disease. Rapid decline, heavy protein, active sediment, absent expected diabetic microvascular context or systemic clues should prompt reconsideration rather than reflex attribution to diabetes. Cardiorenal and hepatorenal syndromes can coexist with CKD. The final diagnosis should state confirmed or provisional chronicity, CGA category, trajectory, leading cause, complications, cardiovascular risk and uncertainties that need follow-up.
Management
Agree priorities with the patient: preserve kidney function where possible, prevent cardiovascular events and AKI, control symptoms and prepare early for possible kidney failure. Treat the cause, including relief of obstruction and specialist therapy for inflammatory or hereditary disease. Monitor eGFR and ACR at a frequency determined by risk and after interventions; small fluctuations occur, so confirm an unexpected decline and inspect volume status, medicines and intercurrent illness before declaring progression.
Blood-pressure management combines standardized measurement, sodium reduction appropriate to the person, activity, weight and medicines. KDIGO suggests a systolic target below 120 mmHg for many non-dialysis adults when measured under standardized conditions and tolerated; this is not interchangeable with a hurried clinic reading and may not suit symptomatic, frail or fall-prone patients. ACE inhibitor or angiotensin-receptor blocker therapy is important in appropriate albuminuric CKD, with creatinine and potassium monitoring after initiation or titration. Avoid routine dual renin-angiotensin blockade.
For eligible people with CKD, sodium-glucose cotransporter-2 inhibitors reduce kidney and cardiovascular outcomes, including in many without diabetes. Selection considers eGFR, albuminuria, heart failure, genital infection risk, volume status, ketoacidosis risk, fasting, surgery and local licence. Diabetes care should avoid both chronic hyperglycaemia and hypoglycaemia as clearance falls. Statin-based therapy and antiplatelet treatment follow cardiovascular indication and bleeding risk, not CKD alone. Smoking cessation, regular feasible activity and individualized dietary advice are foundational.
Manage anaemia, acidosis, potassium, CKD mineral-bone disorder, oedema, pruritus, nutrition and medication burden by measured abnormality and symptoms. Refer early when cause or progression needs specialist care. For advanced CKD, offer shared education about pre-emptive transplant, living or deceased donation pathways, haemodialysis, peritoneal dialysis and comprehensive conservative care. A modality decision includes home conditions, infection risk, vascular anatomy, travel, employment, caregiver burden, affordability and patient goals. Emergency dialysis through an unplanned catheter is an adverse pathway to prevent, not an inevitable stage of CKD.
Prescribing Information
Medication reconciliation is central to CKD care. Record every prescription, over-the-counter analgesic, supplement, herbal product and intermittent antibiotic. Check indication, duplication, adherence, interactions and dose against current kidney function using the method required by the drug and local formulary. eGFR indexed to 1.73 m² may need adjustment for body size for some dosing decisions; creatinine clearance and eGFR are not automatically interchangeable. During rapid change, neither estimate is reliable, so use clinical trajectory, drug levels where available and pharmacy advice.
ACE inhibitors and angiotensin-receptor blockers require baseline and follow-up creatinine and potassium. A modest early filtration change may be expected, but substantial rise, symptomatic hypotension or uncontrolled hyperkalaemia requires assessment for volume depletion, NSAIDs, renal-artery disease, obstruction and dose strategy. Do not stop kidney-protective therapy permanently without reassessing reversible causes and indication. SGLT2 inhibitors can cause a small early eGFR dip; counsel about genital infection, volume status and ketoacidosis warnings and withhold around prolonged fasting, major surgery or severe acute illness under a verified protocol.
Avoid unsupervised NSAIDs and combinations that increase AKI or potassium risk. Metformin, insulin, sulfonylureas, anticoagulants, opioids, gabapentinoids, digoxin, colchicine, antimicrobials and contrast-related plans require medicine-specific review. Antibiotic loading and maintenance may differ; underdosing serious infection is also harmful. Vaccines and infection prophylaxis follow age, stage, planned immunosuppression or kidney-replacement pathway and applicable Indian recommendations.
Anaemia treatment begins by identifying iron deficiency, blood loss, inflammation, B12 or folate deficiency and other causes. Oral or intravenous iron, erythropoiesis-stimulating agents and transfusion have distinct benefits and risks; avoid fixed haemoglobin normalization. Alkali therapy for persistent metabolic acidosis, phosphate binders, vitamin D preparations, calcimimetics and potassium binders should respond to serial data and specialist context. Do not prescribe severe universal potassium, phosphate, protein or fluid restriction without an indication; malnutrition is dangerous. Every medicine plan needs monitoring, stop or review criteria and named result ownership.
When to Refer
Refer to nephrology when cause is uncertain, hereditary or systemic disease is suspected, there is significant persistent albuminuria, albuminuria with haematuria, a sustained rapid decline, resistant hypertension, recurrent hyperkalaemia, acidosis, anaemia or mineral-bone complications not controlled in routine care. A suspected nephritic syndrome, vasculitis, anti-GBM disease, thrombotic microangiopathy, monoclonal process or rapidly progressive loss requires urgent discussion. Recurrent stones, obstruction or structural urological disease may also need urology. Pregnancy, planned pregnancy and childhood CKD require dedicated specialist pathways.
Use eGFR, ACR and a validated kidney-failure risk equation together when appropriate. KDIGO 2024 permits kidney-failure risk to guide referral, multidisciplinary care and preparation, but a locally validated result does not override concerning symptoms, an active sediment or diagnostic uncertainty. Refer advanced CKD early enough for education, transplant evaluation, vaccination, anaemia and bone care, and durable access planning. A late referral after pulmonary oedema or dangerous hyperkalaemia removes meaningful choice.
Kidney-replacement planning should include transplant candidacy and donor discussion, peritoneal dialysis feasibility and haemodialysis vascular assessment. Avoid placing a peripherally inserted central catheter in a potential future dialysis patient without considering vein preservation. Arteriovenous access needs lead time and expert mapping; not every fistula matures and not every person is best served by the same access. Peritoneal dialysis requires home hygiene, storage, training and rapid peritonitis support. Comprehensive conservative care is an active pathway with symptom control, advance care planning and family support, not abandonment.
In India, referral letters should include serial creatinine and potassium, eGFR and ACR, urinalysis, haemoglobin, calcium-phosphate data when relevant, blood-pressure record, ultrasound, medicines and barriers to attendance. Contact the receiving service for urgent deterioration and confirm what dialysis modalities, transplant evaluation and financial support are actually available. A vague instruction to see a kidney doctor is unsafe when travel and appointment delay are substantial.
Red Flags
Urgent assessment is required for breathlessness or hypoxaemia from pulmonary oedema, dangerous hyperkalaemia or ECG change, severe symptomatic acidosis, uraemic encephalopathy, pericarditic pain or rub, seizure, major bleeding, uncontrolled vomiting, rapidly falling urine output or a sudden creatinine rise. These are acute complications or superimposed AKI, not routine chronic follow-up. Dialysis decisions are based on refractory physiological and uraemic problems plus trajectory, not a single creatinine or eGFR threshold.
A rapid fall in eGFR, new heavy albuminuria, visible haematuria with kidney dysfunction, red-cell casts, pulmonary haemorrhage, purpura, haemolysis, thrombocytopenia or severe hypertension suggests inflammatory or vascular disease requiring urgent specialist input. Fever with an obstructed system, transplant symptoms or infected vascular access is time critical. Flank pain, anuria or bladder distension may indicate obstruction. A patient labelled diabetic CKD still needs re-evaluation when the pattern changes abruptly.
Medicine red flags include weakness or palpitations after potassium-raising combinations, hypoglycaemia as insulin clearance falls, opioid or gabapentinoid sedation, bleeding on renally cleared anticoagulation, lactic acidosis risk during severe illness, and rash or systemic symptoms after a new agent. Dehydration, sepsis, diarrhoea and surgery can convert stable CKD into AKI; a written intercurrent-illness plan should state who to contact and when withheld medicines are restarted.
Dialysis-access redness, discharge, fever, loss of fistula thrill, prolonged bleeding, hand pain or ischaemia needs immediate pathway-specific assessment. Peritoneal-dialysis cloudy effluent or abdominal pain is peritonitis until evaluated. Psychosocial red flags include inability to obtain treatment, missed dialysis because of cost or transport, severe symptom burden, caregiver collapse and suicidal thinking. Safe CKD care includes escalation of these threats, not only biochemical surveillance.
Indian Clinical Context
CKD care in India ranges from longitudinal nephrology and transplant programmes to settings where ACR, cystatin C, biopsy, dietetics or dialysis are difficult to access. The minimum reliable pathway is not a long test list: confirm chronicity, record eGFR and urine albumin, investigate remediable causes, control cardiovascular risk, review medicines and arrange result ownership. A peripheral clinician should refer earlier when serial potassium, ultrasound or specialist follow-up cannot be guaranteed. Repeating symptomatic emergency dialysis is not a substitute for an integrated pathway.
Diabetes and hypertension programmes create opportunities for combined screening, but dipstick protein alone misses important disease and one abnormal creatinine creates false labels. Laboratories should report calibrated creatinine and the eGFR equation used, while clinicians should recognize body-composition limits. Cost and distance can make guideline monitoring schedules unrealistic; agree the smallest safe set of tests and a named facility rather than issuing an unaffordable plan that will not occur. Dietary advice should use locally eaten foods, cooking practices, finances and measured potassium or phosphate, preferably with a renal dietitian.
Publicly supported dialysis, state schemes, charitable units and private centres differ in eligibility, consumables, staffing, infection control and transport. Confirm the actual service instead of promising free or universal access. Discuss transplantation early, including living-donor ethics, deceased-donor pathways, immunological assessment, long-term medicines and follow-up costs. Dialysis choice should not be driven only by the machine currently available. Preserve veins, avoid unnecessary central access and create a planned infection-monitoring and vaccination pathway.
Traditional preparations and over-the-counter analgesics should be elicited without ridicule, with packaging retained where possible. Some may be harmless, some nephrotoxic and many compositionally uncertain; chronology alone does not prove causation. International KDIGO and international guidelines recommendations inform this guide but do not replace Indian licensing, formulary, transplant law, local dialysis standards or patient preferences. Shared decisions must document uncertainty, affordability, occupation, family burden and the possibility of comprehensive conservative care.
NMC Competency Mapping
CKD learning integrates renal pathology, medicine, pharmacology, paediatrics, obstetrics and community medicine. The NMC undergraduate curriculum expects learners to understand chronic renal failure causes, pathogenesis, clinical and laboratory manifestations, complications and principles of management. A competent student should define CKD using duration and health implications, distinguish it from AKI, and classify a patient by cause, eGFR and albuminuria rather than using a creatinine label alone.
Clinical skills include retrieving prior results, taking a diabetes, hypertension, urinary, systemic, family and medicine history, measuring blood pressure properly, assessing volume and recognizing uraemic features. Learners should request creatinine with eGFR, quantified urine ACR, urinalysis and appropriately selected imaging. They should interpret G1 through G5 and A1 through A3, know that G1 or G2 alone is not CKD, and recognize limitations of creatinine in unusual muscle mass or non-steady state. Serology, biopsy and genetic testing require an indication and specialist supervision.
Management competencies include cardiovascular risk reduction, blood-pressure and diabetes principles, nephrotoxin avoidance, renal dose review and detection of anaemia, potassium disturbance, acidosis and mineral-bone disorder. Students should explain the rationale for ACE inhibitor or angiotensin-receptor blocker use in albuminuric disease and the expanding role of SGLT2 inhibition without independently prescribing outside supervision. They should recognize emergency dialysis indications and understand haemodialysis, peritoneal dialysis, transplantation and conservative care at a conceptual level.
Communication skills include explaining chronicity, uncertainty, progression risk and monitoring in the patient's language; producing a complete referral; preserving future access veins; and discussing treatment burden without coercion. Curricular mapping does not certify procedural competence in biopsy, dialysis catheter insertion or access surgery. Exact competency codes should be confirmed against the institution's current NMC curriculum implementation before formal assessment use.
Key Exam Pearls for NEET PG
CKD requires kidney structural or functional abnormality for at least three months with health implications. eGFR below 60 qualifies when persistent; G1 or G2 requires another marker of damage. Remember G3 is divided into G3a, 45 to 59, and G3b, 30 to 44. Albuminuria categories are A1 below 30 mg/g, A2 30 to 300 and A3 above 300. CGA classification records cause, G category and A category. A single abnormal result may be AKI or transient albuminuria and needs confirmation.
Albuminuria predicts renal and cardiovascular risk even when eGFR is preserved. Quantified ACR is preferred to a routine dipstick for low-level albumin. Creatinine eGFR is unreliable in acute change and can be biased by muscle mass. Small echogenic kidneys suggest chronicity, but normal or large kidneys occur in diabetes, amyloidosis, infiltration, cystic disease and some other causes.
Progression management is multimodal: treat cause, control blood pressure, use renin-angiotensin blockade for appropriate albuminuric disease, consider SGLT2 inhibition when eligible, address diabetes and lipids, stop smoking, prevent AKI and review every drug dose. Avoid ACE inhibitor plus ARB combination. An initial haemodynamic eGFR dip after appropriate kidney-protective therapy is not automatically toxicity, but substantial decline or hyperkalaemia requires evaluation.
Anaemia is mainly reduced erythropoietin plus iron and inflammatory factors, but exclude blood loss and nutritional causes. Secondary hyperparathyroidism reflects phosphate retention, reduced calcitriol and hypocalcaemic signalling; interpret serial calcium, phosphate, PTH and alkaline phosphatase rather than one value. Metabolic acidosis, hyperkalaemia, fluid overload and uraemic symptoms become more likely with advanced disease. Dialysis is started for refractory complications, symptoms and trajectory, not eGFR alone. Plan transplant and durable access before crisis, and remember that conservative kidney care is a legitimate active treatment pathway.
Frequently Asked Questions
Does one low eGFR test mean that a person has chronic kidney disease?
Not necessarily. CKD requires an abnormality present for at least three months. A new low eGFR may represent acute kidney injury, temporary volume change, medicine effect or laboratory variation. Retrieve older values, repeat testing at a clinically appropriate time and assess urine albumin, urinalysis and cause. Severe or rapidly changing results need urgent assessment rather than delayed confirmation.
Why is urine albumin measured when the eGFR is still normal?
Persistent albuminuria can be an early marker of glomerular injury and independently predicts kidney progression and cardiovascular risk. A person can have G1 or G2 filtration with important A2 or A3 albuminuria. A quantified ACR is more informative than a negative routine dipstick, but transient elevation during fever, exercise, infection or menstruation should be confirmed.
Should all people with chronic kidney disease avoid potassium, protein and fluid?
No. Restrictions should match stage, measured potassium or phosphate, oedema, blood pressure, nutrition, dialysis status and usual diet. Unnecessary restriction can cause malnutrition, constipation and poor quality of life. Sodium moderation is often useful, while protein and potassium plans require individual assessment. A renal dietitian can translate goals into affordable local foods and cooking methods.
When should dialysis or transplant planning begin in chronic kidney disease?
Planning should begin before an emergency when eGFR is declining, kidney-failure risk is substantial or complications are emerging. It includes pre-emptive transplant assessment, modality education, home and caregiver evaluation, vein preservation and timely access planning. The date dialysis starts is based on symptoms, refractory complications and trajectory rather than one eGFR number. Conservative care should be discussed honestly alongside replacement options.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic